Phase 1 trial of tivantinib in combination with sorafenib in adult patients with advanced solid tumors

Investigational New Drugs

Volumn 33, Issue 1, 2015, Pages 159-168

  Puzanov, Igor ^a   Sosman, Jeffrey ^a   Santoro, Armando ^b   Saif, Muhammad W ^c   Goff, Laura ^a   Dy, Grace K ^d   Zucali, Paolo ^b   Means Powell, Julie A ^a   Ma, Wen Wee ^d   Simonelli, Matteo ^b   Martell, Robert ^c   Chai, Feng ^e   Lamar, Maria ^e   Savage, Ronald E ^e   Schwartz, Brian ^e   Adjei, Alex A ^d  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^c TUFTS MEDICAL CENTER   (United States)

^d ROSWELL PARK CANCER INSTITUTE   (United States)

^e ARQULE INC   (United States)

Author keywords

Advanced tumors; MET RTK inhibition; Phase I trial; Sorafenib; Tivantinib; VEGF inhibition

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CYTOCHROME P450 2C19; HEMOGLOBIN; SORAFENIB; TIVANTINIB; 2 PYRROLIDONE DERIVATIVE; ANTINEOPLASTIC AGENT; CARBANILAMIDE DERIVATIVE; CYP2C19 PROTEIN, HUMAN; MET PROTEIN, HUMAN; NICOTINAMIDE; QUINOLINE DERIVATIVE; SCATTER FACTOR RECEPTOR;

ADULT; ADVANCED CANCER; AGED; ALLODYNIA; ALOPECIA; ANEMIA; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; ASTHENIA; BREAST CANCER; CANCER CONTROL; CANCER PATIENT; CANCER TISSUE; COHORT ANALYSIS; DERMATITIS; DERMATITIS ACNEIFORM; DIARRHEA; DIZZINESS; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY SKIN; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FLUSHING; GENETIC POLYMORPHISM; HAND FOOT SYNDROME; HEART ATRIUM FIBRILLATION; HUMAN; HUMAN TISSUE; HYPERTENSION; HYPERURICEMIA; HYPOALBUMINEMIA; HYPOPHOSPHATEMIA; IMMUNOHISTOCHEMISTRY; INTERNATIONAL NORMALIZED RATIO; ITALY; KIDNEY CARCINOMA; LEUKOPENIA; LIMB PAIN; LIVER CELL CARCINOMA; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MELANOMA; MUCOSA INFLAMMATION; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; NON SMALL CELL LUNG CANCER; OUTCOME ASSESSMENT; PHARMACODYNAMICS; PHARMACOGENETICS; PHASE 1 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTHROMBIN TIME; PRURITUS; RASH; RECOMMENDED DRUG DOSE; SIDE EFFECT; SOLID TUMOR; STEADY STATE; STOMATITIS; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; UNITED STATES; VOMITING; WEIGHT REDUCTION; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; GENETICS; METABOLISM; MIDDLE AGED; NEOPLASMS; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYTOCHROME P-450 CYP2C19; FEMALE; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS; NIACINAMIDE; PHENYLUREA COMPOUNDS; POLYMORPHISM, GENETIC; PROTO-ONCOGENE PROTEINS C-MET; PYRROLIDINONES; QUINOLINES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84922092250     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-014-0167-5     Document Type: Article

References (33)

1. Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF (2003) Met, metastasis, motility and more. Nat Rev Mol Cell Biol 4(12):915-925. doi: 10.1038/nrm1261 nrm1261 [pii]
2. Comoglio PM, Giordano S, Trusolino L (2008) Drug development of MET inhibitors: targeting oncogene addiction and expedience. Nat Rev Drug Discov 7(6):504-516. doi: 10.1038/nrd2530
3. Mughal A, Aslam HM, Sheikh A, Khan AM, Saleem S (2013) c-Met inhibitors. Infect Agent Cancer 8(1):13. doi: 10.1186/1750-9378-8-13
4. Liu X, Newton RC, Scherle PA (2010) Developing c-MET pathway inhibitors for cancer therapy: progress and challenges. Trends Mol Med 16(1):37-45. doi: 10.1016/j.molmed.2009.11.005
5. Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO et al (2007) MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316(5827):1039-1043. doi: 10.1126/science.1141478
6. Munshi N, Jeay S, Li Y, Chen CR, France DS, Ashwell MA et al (2010) ARQ 197, a novel and selective inhibitor of the human c-Met receptor tyrosine kinase with antitumor activity. Mol Cancer Ther 9(6):1544-1553. doi: 10.1158/1535-7163.MCT-09-1173
7. Jeay S, Munshi N, Hill J, Moussa MM, Ashwell MA, Leggett DS et al (2007) ARQ 197, a highly selective small molecule inhibitor of c-Met, with selective antitumor properties in a broad spectrum of human cancer cells. Paper presented at the 2007 AACR Annual Meeting, Los Angeles, CA
8. Gherardi E, Birchmeier W, Birchmeier C, Vande Woude G (2012) Targeting MET in cancer: rationale and progress. Nat Rev Cancer 12(2):89-103. doi: 10.1038/nrc3205
9. Jahangiri A, De Lay M, Miller LM, Carbonell WS, Hu YL, Lu K et al (2013) Gene expression profile identifies tyrosine kinase c-Met as a targetable mediator of antiangiogenic therapy resistance. Clin Cancer Res 19(7):1773-1783. doi: 10.1158/1078-0432.CCR-12-1281
10. Chen C-R, Szwaya J, Rojnuckarin A, Uppalapati U, Huang L, Nakuci E, Cornell-Kennon S, Brown J, McSweeney D, Bruseo C, Chan T, France D (2009) Combination studies of tyrosine kinase inhibitors (TKIs): Assessment of potential cytotoxic synergy of ARQ 197 with sorafenib or sunitinib. Proc Am Assoc Cancer Res Apr 18-22; Denver, CO. Philadelphia (PA): AACR 2009: Abstract nr 820
11. Rosen LS, Senzer N, Mekhail T, Ganapathi R, Chai F, Savage RE et al (2011) A phase I dose-escalation study of Tivantinib (ARQ 197) in adult patients with metastatic solid tumors. Clin Cancer Res 17(24):7754-7764. doi: 10.1158/1078-0432.CCR-11-1002
12. Yap TA, Olmos D, Brunetto AT, Tunariu N, Barriuso J, Riisnaes R et al (2011) Phase I trial of a selective c-MET inhibitor ARQ 197 incorporating proof of mechanism pharmacodynamic studies. Am J Clin Oncol 29(10):1271-1279. doi: 10.1200/JCO.2010.31.0367
13. Santoro A, Simonelli M, Rodriguez-Lope C, Zucali P, Camacho LH, Granito A et al (2013) A Phase-1b study of tivantinib (ARQ 197) in adult patients with hepatocellular carcinoma and cirrhosis. Br J Cancer 108(1):21-24. doi: 10.1038/bjc.2012.556
14. Santoro A, Rimassa L, Borbath I, Daniele B, Salvagni S, Van Laethem JL et al (2013) Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study. Lancet Oncol 14(1):55-63. doi: 10.1016/s1470-2045(12)70490-4
15. Goldman JW, Laux I, Chai F, Savage RE, Ferrari D, Garmey EG et al (2012) Phase 1 dose-escalation trial evaluating the combination of the selective MET (mesenchymal-epithelial transition factor) inhibitor tivantinib (ARQ 197) plus erlotinib. Cancer 118(23):5903-5911. doi: 10.1002/cncr.27575
16. Sequist LV, von Pawel J, Garmey EG, Akerley WL, Brugger W, Ferrari D et al (2011) Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer. J Clin Oncol 29(24):3307-3315. doi: 10.1200/JCO.2010.34.0570
17. Natali PG, Prat M, Nicotra MR, Bigotti A, Olivero M, Comoglio PM, Di Renzo MF (1996) Overexpression of the met/HGF receptor in renal cell carcinomas. International journal of cancer Journal international du cancer 69 (3):212-217. doi:10.1002/(SICI) 1097-0215 (19960621) 69:3<212:: AID-IJC11>3.0.CO;2-9 [pii] 10.1002/(SICI) 1097-0215 (19960621) 69:3<212::AID-IJC11>3.0.CO;2-9
18. Pisters LL, el Naggar AK, Luo W, Malpica A, Lin SH (1997) C-met proto-oncogene expression in benign and malignant human renal tissues. Int J Urol 158(3 Pt 1):724-728
19. Gibney GT, Aziz SA, Camp RL, Conrad P, Schwartz BE, Chen CR et al (2013) c-Met is a prognostic marker and potential therapeutic target in clear cell renal cell carcinoma. Ann Oncol 24(2):343-349. doi: 10.1093/annonc/mds463
20. Tavian D, De Petro G, Benetti A, Portolani N, Giulini SM, Barlati S (2000) u-PA and c-MET mRNA expression is co-ordinately enhanced while hepatocyte growth factor mRNA is down-regulated in human hepatocellular carcinoma. Int J Cancer 87(5):644-649
21. Ueki T, Fujimoto J, Suzuki T, Yamamoto H, Okamoto E (1997) Expression of hepatocyte growth factor and its receptor, the c-met proto-oncogene, in hepatocellular carcinoma. J Hepatol 25(3):619-623. doi: 10.1002/hep.510250321
22. Puri N, Ahmed S, Janamanchi V, Tretiakova M, Zumba O, Krausz T et al (2007) c-Met is a potentially new therapeutic target for treatment of human melanoma. Clin Cancer Res 13(7):2246-2253. doi: 10.1158/1078-0432.CCR-06-0776
23. Chattopadhyay C, Ellerhorst JA, Ekmekcioglu S, Greene VR, Davies MA, Grimm EA (2012) Association of activated c-Met with NRAS-mutated human melanomas. Int J Cancer 131(2):E56-E65. doi: 10.1002/ijc.26487
24. National Cancer Institute: Common Terminology Criteria for Adverse Events v3.0 (CTCAE). http://ctep.cancer.gov/protocolDevelopment/electronic-applications/docs/ctcaev3.pdf. Accessed April 30, 2013
25. Bergers G, Hanahan D (2008) Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 8(8):592-603. doi: 10.1038/nrc2442
26. Soda Y, Myskiw C, Rommel A, Verma IM (2013) Mechanisms of neovascularization and resistance to anti-angiogenic therapies in glioblastoma multiforme. J Mol Med (Berl) 91(4):439-448. doi: 10.1007/s00109-013-1019-z
27. Basilico C, Pennacchietti S, Vigna E, Chiriaco C, Arena S, Bardelli A, Valdembri D, Serini G, Michieli P Tivantinib (ARQ197) displays cytotoxic activity that is independent of its ability to bind MET. Clinical cancer research: an official journal of the American Association for Cancer Research 19 (9):2381-2392. doi:1078-0432. CCR-12-3459 [pii] 10.1158/1078-0432.CCR-12-3459
28. Katayama R, Aoyama A, Yamori T, Qi J, Oh-Hara T, Song Y et al (2013) Cytotoxic Activity of Tivantinib (ARQ 197) Is Not Due Solely to c-MET Inhibition. Cancer Res. doi: 10.1158/0008-5472.CAN-12-3256
29. Rini BI, Escudier B, Tomczak P, Kaprin A, Szczylik C, Hutson TE, Michaelson MD, Gorbunova VA, Gore ME, Rusakov IG, Negrier S, Ou YC, Castellano D, Lim HY, Uemura H, Tarazi J, Cella D, Chen C, Rosbrook B, Kim S, Motzer RJ Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet 378 (9807):1931-1939. doi:S0140-6736 (11) 61613-9 [pii] 10.1016/S0140-6736 (11) 61613-9
30. Wagner AJ, Goldberg JM, Dubois SG, Choy E, Rosen L, Pappo A et al (2012) Tivantinib (ARQ 197), a selective inhibitor of MET, in patients with microphthalmia transcription factor-associated tumors: results of a multicenter phase 2 trial. Cancer 118(23):5894-5902. doi: 10.1002/cncr.27582
31. Sattler M, Reddy MM, Hasina R, Gangadhar T, Salgia R (2011) The role of the c-Met pathway in lung cancer and the potential for targeted therapy. Ther Adv Med Oncol 3(4):171-184. doi: 10.1177/1758834011408636
32. Ueki T, Fujimoto J, Suzuki T, Yamamoto H, Okamoto E (1997) Expression of hepatocyte growth factor and its receptor c-met proto-oncogene in hepatocellular carcinoma. Hepatology 25(4):862-866. doi: 10.1002/hep.510250413
33. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Staehler M et al (2009) Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol 27(20):3312-3318. doi: 10.1200/JCO.2008.19.5511